

Funder	Project Title	Funding	Strategic Plan Objective	Institution
FRAXA Research Foundation (FRAXA)	Investigating Gene Reactivation to Treat Fragile X Syndrome	\$0	4.CC	Harvard University, Massachusetts General Hospital
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Project 1	\$0	4.1	The George Washington University
FRAXA Research Foundation (FRAXA)	Recruiting: Fragile X Clinical Trial of New PDE4D Inhibitor from Tetra	\$200,043	4.1	Tetra Discovery Partners & Rush University Medical Center
National Institutes of Health	Integrated Treatments for Core Deficits in Autism Spectrum Disorder	\$146,796	4.1	Rush University Medical Center
Simons Foundation	Modulation of mitochondrial efficiency to treat Fragile X Syndrome	\$146,077	4.1	Yale University
National Institutes of Health	Postnatal Combination Therapy for Cerebral Palsy	\$333,795	4.1	Johns Hopkins University
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Core	\$0	4.1	Yale University
National Institutes of Health	A High-dose Folinic Acid Treatment for Core and Associated Symptoms of Autism	\$558,921	4.1	Phoenix Children'S Hospital
Simons Foundation	Synthetic Infrared Nanosensors for Real-time Monitoring of Oxytocin Release	\$734	4.1	The Regents of the University of California, Berkeley
Autism Speaks	Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism	\$63,700	4.1	Yale University
National Institutes of Health	Transcriptional Signature Profiling of IGF1-Treated Neural Cells from Idiopathic Autistic Patients	\$96,200	4.1	Salk Institute For Biological Studies
Autism Science Foundation	Screening for new autism treatments using cells in a dish	\$0	4.1	University of California, San Diego
National Institutes of Health	Intranasal Vasopressin Treatment in Children with Autism	\$604,364	4.1	Stanford University
Simons Foundation	Development of CRISPRa therapeutics to rescue SCN2A function	\$80,000	4.1	The Regents of the University of California, San Francisco (Contracts & Grants)
Autism Speaks	Response Heterogeneity to GI Treatment, Autism Symptom and Improved Oxidative Stress	\$148,976	4.1	Children's Hospital of Los Angeles
Simons Foundation	Autism synaptic endophenotypes & candidate drug rescue	\$150,000	4.1	Stanford University
Health Resources and Services Administration	A Controlled Trial of Sertraline in Young Children with ASD	\$0	4.1	University of California, Davis
FRAXA Research Foundation (FRAXA)	A Kinase Assay as a Biomarker for Fragile X Syndrome	\$0	4.1	University of Antwerp
National Institutes of Health	Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder	\$534,077	4.1	University of California at Davis
National Institutes of Health	Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD	\$286,244	4.1	University of California Los Angeles
Simons Foundation	Modulation of a splicing regulatory network commonly disrupted in autism	\$150,000	4.1	Governing Council of the University of Toronto

Funder	Project Title	Funding	Strategic Plan Objective	Institution
FRAXA Research Foundation (FRAXA)	Recruiting: Clinical Trial of Metformin for Fragile X Syndrome	\$50,000	4.1	University of Sherbrooke
Simons Foundation	BKCa channels openers for the treatment of sensory hypersensitivity in ASD	\$230,498	4.1	Institut National de la Santé et de la Recherche Médicale-ADR-Bordeaux
Simons Foundation	Randomized Controlled Pilot Trial of Pregnenolone in Autism	\$0	4.1	Stanford University
Simons Foundation	Expr. & character of neuron-specific potassium chloride cotransporter, KCC2	\$100,000	4.1	The Regents of the University of California, San Francisco (Contracts & Grants)
FRAXA Research Foundation (FRAXA)	Repurposing Study II: Evaluating Combinations of Drugs to Treat Fragile X	\$0	4.1	Healx
Simons Foundation	Generating EEG biomarkers of treatment outcome	\$168,468	4.1	Birkbeck College
National Institutes of Health	Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex	\$1,496,413	4.1	University of Alabama at Birmingham
Department of Defense - Army	Early Treatment of Language Impairment in Young Children with Autism Spectrum Disorder with Leucovorin Calcium	\$1,129,610	4.1	Children's Hospital, Phoenix
Department of Defense - Army	Biologic Mechanisms and Efficacy of Cerebellar Transcranial Direct Current Stimulation in ASD	\$713,869	4.1	Texas, University of, Southwestern Medical Center at Dallas
FRAXA Research Foundation (FRAXA)	Fragile X Clinical Trial of AZD7325 in Adults	\$0	4.1	Cincinnati Children's Hospital Medical Center
Brain & Behavior Research Foundation	Mechanism-based Treatment Targets and Biomarkers for Genetically Defined Mental Illnesses	\$25,000	4.1	Cincinnati Children's Hospital Medical Center
Autism Speaks	Double-blind, placebo-controlled target engagement study of minocycline in autism spectrum disorder	\$36,000	4.1	University of Pittsburgh
Autism Speaks	Autism Treatment Network - Pilot study of Minocycline	\$42,000	4.1	Cincinnati Children's Hospital Medical Center
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Project 1	\$0	4.1	The Rector and Visitors of the University of Virginia
Agency for Healthcare Research and Quality	Ambulatory Pediatric Safety Learning Lab	\$560,539	4.1	Cincinnati Children's Hospital Medical Center
National Institutes of Health	Resveratrol-Mediated Regulation of Inflammatory Pathways in Autism Spectrum Disorders	\$219,750	4.1	University of South Carolina at Columbia
Simons Foundation	Safety, Efficacy and Basis of Oxytocin and Brain Stimulation Therapy in ASD	\$0	4.1	University of Pennsylvania
National Institutes of Health	Impact of Combined Medication and Behavioral Treatment in Young Children with Comorbid ASD and ADHD	\$475,076	4.1	Duke University
Department of Defense - Army	Cannabidiol (CBDV) Versus Placebo in Children with Autism Spectrum Disorder (ASD)	\$0	4.1	Albert Einstein College of Medicine

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Autism Research Institute	To study the effect of zinc therapy on ERK levels in individuals with autism	\$7,485	4.1	Hartwick College
Simons Foundation	Structural biological studies of the cytoplasmic domain of KCC2	\$276,992	4.1	New York Structural Biology Center
Department of Defense - Army	Trial of Propranolol in Children and Youth with ASD and Predictors of Response	\$0	4.1	University of Missouri
National Institutes of Health	Rapid, In Vitro Phenotyping of Monogenic Neurological Disorders Using CRISPRi and High-Throughput All-Optical Electrophysiology.	\$550,626	4.1	Q-State Biosciences, Inc.
National Institutes of Health	Development of Roralpha and Rorgamma Ligands for Treatment of Behavioral Disorders	\$59,600	4.1	Saint Louis University
National Institutes of Health	Underlying Mechanisms of Cerebellar tDCS	\$296,254	4.3	New Jersey Institute of Technology
Autism Speaks	Pilot study of Minocycline	\$23,000	4.1	University of Missouri at Columbia
Simons Foundation	Clinical Research Associates	\$1,660,000	4.1	Clinical Research Associates

